Devices that deliver monochromatic infrared energy (MIRE) did not fare any better in reducing foot numbness in individuals with nerve damage due to diabetes, compared with placebo treatments. During the 8-week study, 39 adults with diabetic peripheral neuropathy were randomly treated with MIRE or placebo therapy applied 3 days per week for 4 weeks.
Reporting in Diabetes Care (December 2005), the research team found that 30 minutes of MIRE therapy was not more effective in improving sensation on the sole of the foot, compared with the placebo treatment. MIRE devices were approved by the FDA in the mid-1990s to enhance circulation and reduce pain. The devices have been used in patients with wounds and soft-tissue trauma.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs